Detected ·
Mironid® Limited
$46M—
Mironid® Limited has closed a $46M Series B financing to advance clinical development of its first-in-class treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD), with investors including The Scottish National Investment Bank, Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde.
- Website
- www.mironid.com
- Amount
- $46 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-05 20:06:56 UTC
- Signal ID
- dfdac80f-b4e1-4ecf-b3dd-309bac3bbf83
As the API returns it
{
"id": "dfdac80f-b4e1-4ecf-b3dd-309bac3bbf83",
"created_at": "2026-08-05T20:06:56.721997Z",
"company_name": "Mironid® Limited",
"company_website_url": "www.mironid.com",
"company_linkedin_url": "https://www.linkedin.com/company/mironid-limited",
"event_type": "funding",
"funding_amount": 46000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Mironid® Limited has closed a $46M Series B financing to advance clinical development of its first-in-class treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD), with investors including The Scottish National Investment Bank, Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde.*"
}